Therapeutic challenges for concurrent ethanol and nicotine consumption: naltrexone and varenicline fail to alter simultaneous ethanol and nicotine intake by female alcohol-preferring (P) rats

Robert A. Waeiss, Christopher P. Knight, Sheketha R. Hauser, Lauren A. Pratt, William J. McBride, Zachary Rodd

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Rationale and objectives: Simultaneous alcohol and nicotine consumption occurs in the majority of individuals with alcohol use disorder (AUD) and nicotine dependence. Varenicline (Var) is used to assist in the cessation of nicotine use, while naltrexone (Nal) is the standard treatment for AUD. Despite evidence that ethanol (EtOH) and nicotine (NIC) co-use produces unique neuroadaptations, preclinical research has focused on the effects of pharmacotherapeutics on a single reinforcer. The current experiments examined the effects of Var and Nal on EtOH, NIC, or EtOH+NIC intake. Methods: Animals were randomly assigned to one of four drinking conditions of 24-h access to a three-bottle choice paradigm, one of which always contained water. Drinking conditions were water only, 0.07 and 0.14 mg/mL NIC (NIC only), 15% and 30% EtOH (EtOH only), or 15% and 30% EtOH with 0.14 mg/mL NIC (EtOH+NIC). The effects of Var (0, 1, or 2 mg/kg) or Nal (0, 1, or 10 mg/kg) injections on maintenance and relapse consumption were determined during four consecutive days. Results: Var reduced maintenance and relapse NIC intake but had no effect on EtOH or EtOH+NIC drinking. Conversely, Nal reduced EtOH maintenance and relapse drinking, but had no effect on NIC or EtOH+NIC drinking. Discussion: The results indicate the standard pharmacological treatments for nicotine dependence and AUD were effective at reducing consumption of the targeted reinforcer but neither reduced EtOH+NIC co-use/abuse. These findings suggest that co-abuse may promote unique neuroadaptations that require models of polysubstance abuse to develop pharmacotherapeutics to treat AUD and nicotine dependence.

Original languageEnglish (US)
JournalPsychopharmacology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Naltrexone
Nicotine
Ethanol
Alcohols
Drinking
Tobacco Use Disorder
Therapeutics
Maintenance
Varenicline
Recurrence
Water
Alcohol Drinking

Keywords

  • Addiction
  • Alcohol
  • Alcohol-preferring (P) rats
  • Co-abuse
  • Ethanol
  • Maintenance
  • Naltrexone
  • Nicotine
  • Relapse
  • Varenicline

ASJC Scopus subject areas

  • Pharmacology

Cite this

Therapeutic challenges for concurrent ethanol and nicotine consumption : naltrexone and varenicline fail to alter simultaneous ethanol and nicotine intake by female alcohol-preferring (P) rats. / Waeiss, Robert A.; Knight, Christopher P.; Hauser, Sheketha R.; Pratt, Lauren A.; McBride, William J.; Rodd, Zachary.

In: Psychopharmacology, 01.01.2019.

Research output: Contribution to journalArticle

@article{5eb4ea34fce245f9ab18ce0fc8b6df89,
title = "Therapeutic challenges for concurrent ethanol and nicotine consumption: naltrexone and varenicline fail to alter simultaneous ethanol and nicotine intake by female alcohol-preferring (P) rats",
abstract = "Rationale and objectives: Simultaneous alcohol and nicotine consumption occurs in the majority of individuals with alcohol use disorder (AUD) and nicotine dependence. Varenicline (Var) is used to assist in the cessation of nicotine use, while naltrexone (Nal) is the standard treatment for AUD. Despite evidence that ethanol (EtOH) and nicotine (NIC) co-use produces unique neuroadaptations, preclinical research has focused on the effects of pharmacotherapeutics on a single reinforcer. The current experiments examined the effects of Var and Nal on EtOH, NIC, or EtOH+NIC intake. Methods: Animals were randomly assigned to one of four drinking conditions of 24-h access to a three-bottle choice paradigm, one of which always contained water. Drinking conditions were water only, 0.07 and 0.14 mg/mL NIC (NIC only), 15{\%} and 30{\%} EtOH (EtOH only), or 15{\%} and 30{\%} EtOH with 0.14 mg/mL NIC (EtOH+NIC). The effects of Var (0, 1, or 2 mg/kg) or Nal (0, 1, or 10 mg/kg) injections on maintenance and relapse consumption were determined during four consecutive days. Results: Var reduced maintenance and relapse NIC intake but had no effect on EtOH or EtOH+NIC drinking. Conversely, Nal reduced EtOH maintenance and relapse drinking, but had no effect on NIC or EtOH+NIC drinking. Discussion: The results indicate the standard pharmacological treatments for nicotine dependence and AUD were effective at reducing consumption of the targeted reinforcer but neither reduced EtOH+NIC co-use/abuse. These findings suggest that co-abuse may promote unique neuroadaptations that require models of polysubstance abuse to develop pharmacotherapeutics to treat AUD and nicotine dependence.",
keywords = "Addiction, Alcohol, Alcohol-preferring (P) rats, Co-abuse, Ethanol, Maintenance, Naltrexone, Nicotine, Relapse, Varenicline",
author = "Waeiss, {Robert A.} and Knight, {Christopher P.} and Hauser, {Sheketha R.} and Pratt, {Lauren A.} and McBride, {William J.} and Zachary Rodd",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s00213-019-5174-y",
language = "English (US)",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Therapeutic challenges for concurrent ethanol and nicotine consumption

T2 - naltrexone and varenicline fail to alter simultaneous ethanol and nicotine intake by female alcohol-preferring (P) rats

AU - Waeiss, Robert A.

AU - Knight, Christopher P.

AU - Hauser, Sheketha R.

AU - Pratt, Lauren A.

AU - McBride, William J.

AU - Rodd, Zachary

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Rationale and objectives: Simultaneous alcohol and nicotine consumption occurs in the majority of individuals with alcohol use disorder (AUD) and nicotine dependence. Varenicline (Var) is used to assist in the cessation of nicotine use, while naltrexone (Nal) is the standard treatment for AUD. Despite evidence that ethanol (EtOH) and nicotine (NIC) co-use produces unique neuroadaptations, preclinical research has focused on the effects of pharmacotherapeutics on a single reinforcer. The current experiments examined the effects of Var and Nal on EtOH, NIC, or EtOH+NIC intake. Methods: Animals were randomly assigned to one of four drinking conditions of 24-h access to a three-bottle choice paradigm, one of which always contained water. Drinking conditions were water only, 0.07 and 0.14 mg/mL NIC (NIC only), 15% and 30% EtOH (EtOH only), or 15% and 30% EtOH with 0.14 mg/mL NIC (EtOH+NIC). The effects of Var (0, 1, or 2 mg/kg) or Nal (0, 1, or 10 mg/kg) injections on maintenance and relapse consumption were determined during four consecutive days. Results: Var reduced maintenance and relapse NIC intake but had no effect on EtOH or EtOH+NIC drinking. Conversely, Nal reduced EtOH maintenance and relapse drinking, but had no effect on NIC or EtOH+NIC drinking. Discussion: The results indicate the standard pharmacological treatments for nicotine dependence and AUD were effective at reducing consumption of the targeted reinforcer but neither reduced EtOH+NIC co-use/abuse. These findings suggest that co-abuse may promote unique neuroadaptations that require models of polysubstance abuse to develop pharmacotherapeutics to treat AUD and nicotine dependence.

AB - Rationale and objectives: Simultaneous alcohol and nicotine consumption occurs in the majority of individuals with alcohol use disorder (AUD) and nicotine dependence. Varenicline (Var) is used to assist in the cessation of nicotine use, while naltrexone (Nal) is the standard treatment for AUD. Despite evidence that ethanol (EtOH) and nicotine (NIC) co-use produces unique neuroadaptations, preclinical research has focused on the effects of pharmacotherapeutics on a single reinforcer. The current experiments examined the effects of Var and Nal on EtOH, NIC, or EtOH+NIC intake. Methods: Animals were randomly assigned to one of four drinking conditions of 24-h access to a three-bottle choice paradigm, one of which always contained water. Drinking conditions were water only, 0.07 and 0.14 mg/mL NIC (NIC only), 15% and 30% EtOH (EtOH only), or 15% and 30% EtOH with 0.14 mg/mL NIC (EtOH+NIC). The effects of Var (0, 1, or 2 mg/kg) or Nal (0, 1, or 10 mg/kg) injections on maintenance and relapse consumption were determined during four consecutive days. Results: Var reduced maintenance and relapse NIC intake but had no effect on EtOH or EtOH+NIC drinking. Conversely, Nal reduced EtOH maintenance and relapse drinking, but had no effect on NIC or EtOH+NIC drinking. Discussion: The results indicate the standard pharmacological treatments for nicotine dependence and AUD were effective at reducing consumption of the targeted reinforcer but neither reduced EtOH+NIC co-use/abuse. These findings suggest that co-abuse may promote unique neuroadaptations that require models of polysubstance abuse to develop pharmacotherapeutics to treat AUD and nicotine dependence.

KW - Addiction

KW - Alcohol

KW - Alcohol-preferring (P) rats

KW - Co-abuse

KW - Ethanol

KW - Maintenance

KW - Naltrexone

KW - Nicotine

KW - Relapse

KW - Varenicline

UR - http://www.scopus.com/inward/record.url?scp=85061476277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061476277&partnerID=8YFLogxK

U2 - 10.1007/s00213-019-5174-y

DO - 10.1007/s00213-019-5174-y

M3 - Article

C2 - 30758525

AN - SCOPUS:85061476277

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

ER -